Skip to main content
Log in
Clinical and Translational Imaging

Official Journal of the Italian Association of Nuclear Medicine and Molecular Imaging

Publishing model:

Submission guidelines

Contents

Instructions for Authors

General information

Editorial Procedure

Clinical and Translational Imaging is the official journal of the Italian Association of Nuclear Medicine and Molecular Imaging. It publishes invited and freely submitted originals and review papers from all over the world in the field of nuclear medicine and molecular imaging.

All manuscripts must be submitted online and are due to peer review.

Language

Manuscripts that are accepted for publication will be checked by our copyeditors for spelling and formal style. If English is not your native language, this copyediting may not be sufficient. To avoid the need for substantial editing, you may want to have your manuscript edited by a native speaker prior to submission. The use of clear and concise language will help editors and reviewers concentrate on the scientific content of your paper and thus expedite the peer review process.

Authorship

Authorship should meet international publishing standards. The International Committee of Medical Journal Editors (ICMJE) recommends that authorship should be based on substantial contribution to:

  • (a) Conception and design of the article, or acquisition, analysis and interpretation of data;
  • (b) Drafting of the article or critical revision for important intellectual content; and
  • (c) Final approval of the version to be published.

Conditions (a), (b), and (c) must all be met by each author. Each author must also be prepared to take public responsibility for the article.

The order of authors should be the joint decision of all the authors.

Each manuscript should contain a statement about the authors' contribution to the Manuscript.

This should be placed before the reference list at the end of the manuscript.

List each author by surname (family name) and describe each of their contributions (select all that apply) to the manuscript using the following terms. Inclusion of people that have given non substantial contribution (honorary authorship) and exclusion of authors that have given substantial contribution is considered as an act of scientific misconduct.

• Literature search

• Literature review

• Meta-analysis

• Writing

• Editing

• Content planning

• Other (e. g. protocol/project development, data collection or management, data analysis etc.); please specify briefly using 1 to 5 words

For example:

AR Smith: Literature Search and Review, Manuscript Writing

TS Jones: Meta-Analysis and Content planning

AJ Davis: Manuscript writing and Editing

Open Choice publication

Springer Open Choice program allows authors to publish open access. The final published version will become freely available on PubMed Central/Europe PMC, the full-text archive of scientific literature in the biomedical and life sciences.

Publishing Open Choice involves an open access publication fee, anyway many Universities and Institutions worldwide have created funds dedicated to cover some or all of the open access publication cost for their researchers, faculty or members. Please ask your institution whether any agreement with Springer is in place for sponsoring open access publication or visit our open access funding page to find out how the open access publication charge can be covered.

You can decide to publish your article with open access during the MyPublication process. Once your article has been accepted for publication, you will receive an email from Springer with a link to your MyPublication pages. In these pages you can choose for your article to be published with open access.

Springer Open Choice

Open Access funding page

MyPublication process

Obtaining permission to reuse Springer content

If authors wish to reuse Springer content in articles already published, they need to obtain permission. In order to provide a fast and easy service Springer has an online form for permission requests in place. Authors can use this online service to ensure prompt handling of their request.

Please find a detailed step-by-step description for requesting permission to reuse Springer content here:

Link

Types of papers

Original Articles– PLEASE SUBMIT AS RESEARCH ARTICLES

Original article should report scientifically sound experiments and provide new information. It should contain no more than 5000 words (including abstract, introduction; methods; results; discussion, disclosure, and acknowledgment). Abstracts should be structured and should contain a maximum of 300 words. Original Articles should contain a maximum of 5 tables and/or figures (more can be included as supplementary material). Please include within your manuscript the Name of the registry and the URL of trial registry record of your trial registration at the end of your abstract. More information about trial registration, including the trial registries that currently meet all of the ICMJE guidelines, can be found in the FAQ section of “About ICMJE” at http://www.icmje.org/about-icmje/faqs/clinical-trials-registration.

Both in the review article and original article, the authors are invited to include a separate section called "Key Points" at the end of the manuscript. This feature provides a quick explanation of the main findings of the manuscript, following 3 key points. Limit this section to 100-150 words or less.

Reviews – PLEASE SUBMIT AS REVIEW

Reviews articles aim to provide substantial coverage and critical appraisal of results, progresses and innovations concerning diagnostic or therapeutic procedures, in well-defined areas of nuclear medicine and molecular imaging.

Papers should be comprehensive but focused. There are no restrictions regarding references, figures, or word count, however, between 4000 and 9000 words, and between 50 and 100 references, plus figures and tables, with detailed legends, are deemed adequate.

Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references and should be arranged in four sections:

• Purpose (stating the aim of the review)

• Methods (indicating the literature search strategy, i.e. data base searched, the inclusion and exclusion criteria and any other item, including guidelines followed, related to the methodology used).

• Results (indicating the number of papers retrieved from the initial search and that of those eventually considered for the review, followed by the findings and the results of clinical relevance)

• Conclusions (summarizing the evidences resulting from the review followed by clinical/practical recommendations)

Three types of reviews are considered: Systematic Reviews, Meta-Analyses and Expert Reviews. It is strongly recommended that meta-analyses and systematic reviews comply with the PRISMA Statement, which is available

here

Meta-Analysis (as defined by PubMed)– PLEASE SUBMIT AS REVIEW

Works consisting of studies using a quantitative method of combining the results of independent studies (usually drawn from the published literature) and synthesizing summaries and conclusions which may be used to evaluate therapeutic effectiveness, plan new studies, etc. It is often an overview of clinical trials. It is usually called a meta-analysis by the author or sponsoring body and should be differentiated from reviews of literature.

Systematic Review (as defined by PubMed)– PLEASE SUBMIT AS REVIEW

An article published after examination of published material on a subject. It may be comprehensive to various degrees and the time range of material scrutinized may be broad or narrow, but the reviews most often desired are reviews of the current literature. The textual material examined may be equally broad and can encompass, in medicine specifically, clinical material as well as experimental research or case reports.

Expert Review– PLEASE SUBMIT AS REVIEW

Expert reviews re an equivalent of narrative reviews, they present and critically evaluate emerging topics based on the selection of important references in the current literature; they are based mainly on the experience of the authors, and report the author's vision of future developments and research directions in the area.

- - -

Additionally five other types of papers are welcome:

Spotlights – PLEASE SUBMIT AS COMMENTS

The Spotlight contribution is a short text of approx. two printed pages with neither an abstract nor keywords. It should be between 1,000 and 1,400 words long and include a maximum of three references. Essentially a commentary, it should be quite provocative, sparking discussions on emerging issues and on general problems under discussion in the scientific community.

Editorials - upon invitation only, to be sent to EIC directly

Editorials should be aimed at presenting a synthetic, yet in depth, critical appraisal of the most recent advances in the field of Nuclear Medicine and Molecular Imaging in view of previous knowledge. They are also the medium for the discussion and/or exchange of opinions regarding previous publications in Clinical and translational Imaging or in other publications, Editorials should not include either an abstract or keywords, should be between 1000 and 1400 words long, and should include a maximum of three references.

Pictorial Essay – PLEASE SUBMIT AS RESEARCH ARTICLE

Pictorial essay should be aimed at presenting a large number of images collated by the authors, accompanied by detailed legends presenting the author's experience in the area. Pictorial essay should be between 1000 and 1400 words long (excluding legends), and should include up to a maximum of 30 references. Please check the Artwork and Illustrations Guidelines provided in the Instructions for Authors for more details on electronic figure submission.

Mini-review – PLEASE SUBMIT AS MINI-REVIEW

The mini-review is a text of approximately four-five pages. It should be between 2000-3000 words long (including the abstract). Essentially a concise, focused review related to an issue of current interest in the scientific community, commenting the most relevant developments based on up-to-date articles.

Letter to the Editor– PLEASE SUBMIT AS CORRESPONDENCE

A Letter to the Editor should present an objective and constructive criticism of published articles.

Manuscript Submission

Manuscript Submission

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Permissions

Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission

Please follow the hyperlink “Submit manuscript” and upload all of your manuscript files following the instructions given on the screen.

Source Files

Please ensure you provide all relevant editable source files at every submission and revision. Failing to submit a complete set of editable source files will result in your article not being considered for review. For your manuscript text please always submit in common word processing formats such as .docx or LaTeX.

Submitting Declarations

Please note that Author Contribution information and Competing Interest information must be provided at submission via the submission interface. Only the information submitted via the interface will be used in the final published version. Please make sure that if you are an editorial board member and also a listed author that you also declare this information in the Competing Interest section of the interface.

Please see the relevant sections in the submission guidelines for further information on these statements as well as possible other mandatory statements.

Scientific style

  • Please always use internationally accepted signs and symbols for units (SI units).
  • Genus and species names should be in italics.
  • Generic names of drugs and pesticides are preferred; if trade names are used, the generic name should be given at first mention.

Title Page

Please make sure your title page contains the following information.

Title

The title should be concise and informative.

Author information

  • The name(s) of the author(s)
  • The affiliation(s) of the author(s), i.e. institution, (department), city, (state), country
  • A clear indication and an active e-mail address of the corresponding author
  • If available, the 16-digit ORCID of the author(s)

If address information is provided with the affiliation(s) it will also be published.

For authors that are (temporarily) unaffiliated we will only capture their city and country of residence, not their e-mail address unless specifically requested.

Large Language Models (LLMs), such as ChatGPT, do not currently satisfy our authorship criteria. Notably an attribution of authorship carries with it accountability for the work, which cannot be effectively applied to LLMs. Use of an LLM should be properly documented in the Methods section (and if a Methods section is not available, in a suitable alternative part) of the manuscript.

Abstract

Please provide a structured abstract of 150 to 250 words which should be divided into the following sections:

  • Purpose (stating the main purposes and research question)
  • Methods
  • Results
  • Conclusion

For life science journals only (when applicable)

  • Trial registration number and date of registration for prospectively registered trials
  • Trial registration number and date of registration followed by “retrospectively registered”, for retrospectively registered trials

Keywords

Please provide 4 to 6 keywords which can be used for indexing purposes.

Statements and Declarations

The following statements should be included under the heading "Statements and Declarations" for inclusion in the published paper. Please note that submissions that do not include relevant declarations will be returned as incomplete.

  • Competing Interests: Authors are required to disclose financial or non-financial interests that are directly or indirectly related to the work submitted for publication. Please refer to “Competing Interests and Funding” below for more information on how to complete this section.

Please see the relevant sections in the submission guidelines for further information as well as various examples of wording. Please revise/customize the sample statements according to your own needs.

Specific Remark to Abstract

Reviews (Meta-analysis reviews, Systematic reviews, expert reviews, and mini-reviews)

Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references and should be arranged in four sections:

• Purpose (stating the aim of the review)

• Methods (indicating the literature search strategy, i.e. data base searched, the inclusion and exclusion criteria and any other item, including guidelines followed, related to the methodology used).

• Results (indicating the number of papers retrieved from the initial search and that of those eventually considered for the review, followed by the findings and the results of clinical relevance)

• Conclusions (summarizing the evidences resulting from the review followed by clinical/practical recommendations)

Pictorial Essays

Please provide an unstructured abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references and should describe, after a short background, the aim of the pictorial essay, the source of the images and cases presented, main observations and conclusions, summarizing the evidences resulting from the pictorial assay followed by clinical/practical recommendations

Spotlights and Editorial

These type of papers should not have an abstract.

Text

Text Formatting

Manuscripts should be submitted in Word.

  • Use a normal, plain font (e.g., 10-point Times Roman) for text.
  • Use italics for emphasis.
  • Use the automatic page numbering function to number the pages.
  • Do not use field functions.
  • Use tab stops or other commands for indents, not the space bar.
  • Use the table function, not spreadsheets, to make tables.
  • Use the equation editor or MathType for equations.
  • Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).

Headings

Please use no more than three levels of displayed headings.

Abbreviations

Abbreviations should be defined at first mention and used consistently thereafter.

Footnotes

Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.

Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.

Always use footnotes instead of endnotes.

Acknowledgments

Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organizations should be written in full.

References

Citation

Reference citations in the text should be identified by numbers in square brackets. Some examples:

1. Negotiation research spans many disciplines [3].

2. This result was later contradicted by Becker and Seligman [5].

3. This effect has been widely studied [1-3, 7].

Reference list

The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text.

The entries in the list should be numbered consecutively.

If available, please always include DOIs as full DOI links in your reference list (e.g. “https://doi.org/abc”).

  • Journal article

    Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L (2009) Effect of high intensity intermittent training on heart rate variability in prepubescent children. Eur J Appl Physiol 105:731-738. https://doi.org/10.1007/s00421-008-0955-8

    Ideally, the names of all authors should be provided, but the usage of “et al” in long author lists will also be accepted:

    Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. N Engl J Med 965:325–329

  • Article by DOI

    Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med. https://doi.org/10.1007/s001090000086

  • Book

    South J, Blass B (2001) The future of modern genomics. Blackwell, London

  • Book chapter

    Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern genomics, 3rd edn. Wiley, New York, pp 230-257

  • Online document

    Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007

  • Dissertation

    Trent JW (1975) Experimental acute renal failure. Dissertation, University of California

Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see

ISSN.org LTWA

If you are unsure, please use the full journal title.

Authors preparing their manuscript in LaTeX can use the bibliography style file sn-basic.bst which is included in the Springer Nature Article Template.

Tables

  • All tables are to be numbered using Arabic numerals.
  • Tables should always be cited in text in consecutive numerical order.
  • For each table, please supply a table caption (title) explaining the components of the table.
  • Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
  • Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.

Artwork and Illustrations Guidelines

Electronic Figure Submission

  • Supply all figures electronically.
  • Indicate what graphics program was used to create the artwork.
  • For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MSOffice files are also acceptable.
  • Vector graphics containing fonts must have the fonts embedded in the files.
  • Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.

Line Art

  • Definition: Black and white graphic with no shading.
  • Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
  • All lines should be at least 0.1 mm (0.3 pt) wide.
  • Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.
  • Vector graphics containing fonts must have the fonts embedded in the files.

Halftone Art

  • Definition: Photographs, drawings, or paintings with fine shading, etc.
  • If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.
  • Halftones should have a minimum resolution of 300 dpi.

Combination Art

  • Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
  • Combination artwork should have a minimum resolution of 600 dpi.

Color Art

  • Color art is free of charge for online publication.
  • If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
  • If the figures will be printed in black and white, do not refer to color in the captions.
  • Color illustrations should be submitted as RGB (8 bits per channel).

Figure Lettering

  • To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
  • Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).
  • Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
  • Avoid effects such as shading, outline letters, etc.
  • Do not include titles or captions within your illustrations.

Figure Numbering

  • All figures are to be numbered using Arabic numerals.
  • Figures should always be cited in text in consecutive numerical order.
  • Figure parts should be denoted by lowercase letters (a, b, c, etc.).
  • If an appendix appears in your article and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures,"A1, A2, A3, etc." Figures in online appendices [Supplementary Information (SI)] should, however, be numbered separately.

Figure Captions

  • Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
  • Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
  • No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
  • Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
  • Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

Figure Placement and Size

  • Figures should be submitted within the body of the text. Only if the file size of the manuscript causes problems in uploading it, the large figures should be submitted separately from the text.
  • When preparing your figures, size figures to fit in the column width.
  • For large-sized journals the figures should be 84 mm (for double-column text areas), or 174 mm (for single-column text areas) wide and not higher than 234 mm.
  • For small-sized journals, the figures should be 119 mm wide and not higher than 195 mm.

Permissions

If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

Accessibility

In order to give people of all abilities and disabilities access to the content of your figures, please make sure that

  • All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware)
  • Patterns are used instead of or in addition to colors for conveying information (colorblind users would then be able to distinguish the visual elements)
  • Any figure lettering has a contrast ratio of at least 4.5:1

Generative AI Images

Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein.

Supplementary Information (SI)

Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online along with an article or a book chapter. This feature can add dimension to the author's article, as certain information cannot be printed or is more convenient in electronic form.

Before submitting research datasets as Supplementary Information, authors should read the journal’s Research data policy. We encourage research data to be archived in data repositories wherever possible.

Submission

  • Supply all supplementary material in standard file formats.
  • Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
  • To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.
  • High resolution (streamable quality) videos can be submitted up to a maximum of 25GB; low resolution videos should not be larger than 5GB.

Audio, Video, and Animations

  • Aspect ratio: 16:9 or 4:3
  • Maximum file size: 25 GB for high resolution files; 5 GB for low resolution files
  • Minimum video duration: 1 sec
  • Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts, m4v, 3gp

Text and Presentations

  • Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
  • A collection of figures may also be combined in a PDF file.

Spreadsheets

  • Spreadsheets should be submitted as .csv or .xlsx files (MS Excel).

Specialized Formats

  • Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.

Collecting Multiple Files

  • It is possible to collect multiple files in a .zip or .gz file.

Numbering

  • If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables.
  • Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", “... additional data are given in Online Resource 4”.
  • Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.

Captions

  • For each supplementary material, please supply a concise caption describing the content of the file.

Processing of supplementary files

  • Supplementary Information (SI) will be published as received from the author without any conversion, editing, or reformatting.

Accessibility

In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that

  • The manuscript contains a descriptive caption for each supplementary material
  • Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)

Generative AI Images

Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein.

Research Data Policy and Data Availability Statements

This journal follows Springer Nature research data policy. Sharing of all relevant research data is strongly encouraged and authors must add a Data Availability Statement to original research articles.

Research data includes a wide range of types, including spreadsheets, images, textual extracts, archival documents, video or audio, interview notes or any specialist formats generated during research.

Data availability statements

All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here.

If it is not possible to share research data publicly, for instance when individual privacy could be compromised, this statement should describe how data can be accessed and any conditions for reuse. Participant consent should be obtained and documented prior to data collection. See our guidance on sensitive data for more information.

When creating a data availability statement, authors are encouraged to consider the minimal dataset that would be necessary to interpret, replicate and build upon the findings reported in the article.

Further guidance on writing a data availability statement, including examples, is available at:

Data availability statements

Data repositories

Authors are strongly encouraged to deposit their supporting data in a publicly available repository. Sharing your data in a repository promotes the integrity, discovery and reuse of your research, making it easier for the research community to build on and credit your work.

See our data repository guidance for information on finding a suitable repository.

We recommend the use of discipline-specific repositories where available. For a number of data types, submission to specific public repositories is mandatory.

See our list of mandated data types.

The journal encourages making research data available under open licences that permit reuse. The journal does not enforce use of particular licences in third party repositories. You should ensure you have necessary rights to share any data that you deposit in a repository.

Data citation

The journal recommends that authors cite any publicly available data on which the conclusions of the paper rely. This includes data the authors are sharing alongside their publication and any secondary data the authors have reused. Data citations should include a persistent identifier (such as a DOI), should be included in the reference list using the minimum information recommended by DataCite (Dataset Creator, Dataset Title, Publisher [repository], Publication Year, Identifier [e.g. DOI, Handle, Accession or ARK]) and follow journal style.

See our further guidance on citing datasets.

Research data and peer review

If the journal that you are submitting to uses double-anonymous peer review and you are providing reviewers with access to your data (for example via a repository link, supplementary information or data on request), it is strongly suggested that the authorship in the data is also anonymised. There are data repositories that can assist with this and/or will create a link to mask the authorship of your data.

Support with research data policy

Authors who need help understanding our data sharing policy, finding a suitable data repository, or organising and sharing research data can consult our Research Data Helpdesk for guidance.

See our FAQ page for more information on Springer Nature’s research data policy.

Ethical Responsibilities of Authors

This journal is committed to upholding the integrity of the scientific record. As a member of the Committee on Publication Ethics (COPE) the journal will follow the COPE guidelines on how to deal with potential acts of misconduct.

Authors should refrain from misrepresenting research results which could damage the trust in the journal, the professionalism of scientific authorship, and ultimately the entire scientific endeavour. Maintaining integrity of the research and its presentation is helped by following the rules of good scientific practice, which include*:

  • The manuscript should not be submitted to more than one journal for simultaneous consideration.
  • The submitted work should be original and should not have been published elsewhere in any form or language (partially or in full), unless the new work concerns an expansion of previous work. (Please provide transparency on the re-use of material to avoid the concerns about text-recycling (‘self-plagiarism’).
  • A single study should not be split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time (i.e. ‘salami-slicing/publishing’).
  • Concurrent or secondary publication is sometimes justifiable, provided certain conditions are met. Examples include: translations or a manuscript that is intended for a different group of readers.
  • Results should be presented clearly, honestly, and without fabrication, falsification or inappropriate data manipulation (including image based manipulation). Authors should adhere to discipline-specific rules for acquiring, selecting and processing data.
  • No data, text, or theories by others are presented as if they were the author’s own (‘plagiarism’). Proper acknowledgements to other works must be given (this includes material that is closely copied (near verbatim), summarized and/or paraphrased), quotation marks (to indicate words taken from another source) are used for verbatim copying of material, and permissions secured for material that is copyrighted.

Important note: the journal may use software to screen for plagiarism.

  • Authors should make sure they have permissions for the use of software, questionnaires/(web) surveys and scales in their studies (if appropriate).
  • Research articles and non-research articles (e.g. Opinion, Review, and Commentary articles) must cite appropriate and relevant literature in support of the claims made. Excessive and inappropriate self-citation or coordinated efforts among several authors to collectively self-cite is strongly discouraged.
  • Authors should avoid untrue statements about an entity (who can be an individual person or a company) or descriptions of their behavior or actions that could potentially be seen as personal attacks or allegations about that person.
  • Research that may be misapplied to pose a threat to public health or national security should be clearly identified in the manuscript (e.g. dual use of research). Examples include creation of harmful consequences of biological agents or toxins, disruption of immunity of vaccines, unusual hazards in the use of chemicals, weaponization of research/technology (amongst others).
  • Authors are strongly advised to ensure the author group, the Corresponding Author, and the order of authors are all correct at submission. Adding and/or deleting authors during the revision stages is generally not permitted, but in some cases may be warranted. Reasons for changes in authorship should be explained in detail. Please note that changes to authorship cannot be made after acceptance of a manuscript.

*All of the above are guidelines and authors need to make sure to respect third parties rights such as copyright and/or moral rights.

Upon request authors should be prepared to send relevant documentation or data in order to verify the validity of the results presented. This could be in the form of raw data, samples, records, etc. Sensitive information in the form of confidential or proprietary data is excluded.

If there is suspicion of misbehavior or alleged fraud the Journal and/or Publisher will carry out an investigation following COPE guidelines. If, after investigation, there are valid concerns, the author(s) concerned will be contacted under their given e-mail address and given an opportunity to address the issue. Depending on the situation, this may result in the Journal’s and/or Publisher’s implementation of the following measures, including, but not limited to:

  • If the manuscript is still under consideration, it may be rejected and returned to the author.
  • If the article has already been published online, depending on the nature and severity of the infraction:

    - an erratum/correction may be placed with the article

    - an expression of concern may be placed with the article

    - or in severe cases retraction of the article may occur.

The reason will be given in the published erratum/correction, expression of concern or retraction note. Please note that retraction means that the article is maintained on the platform, watermarked “retracted” and the explanation for the retraction is provided in a note linked to the watermarked article.

  • The author’s institution may be informed
  • A notice of suspected transgression of ethical standards in the peer review system may be included as part of the author’s and article’s bibliographic record.

Fundamental errors

Authors have an obligation to correct mistakes once they discover a significant error or inaccuracy in their published article. The author(s) is/are requested to contact the journal and explain in what sense the error is impacting the article. A decision on how to correct the literature will depend on the nature of the error. This may be a correction or retraction. The retraction note should provide transparency which parts of the article are impacted by the error.

Suggesting / excluding reviewers

Authors are welcome to suggest suitable reviewers and/or request the exclusion of certain individuals when they submit their manuscripts. When suggesting reviewers, authors should make sure they are totally independent and not connected to the work in any way. It is strongly recommended to suggest a mix of reviewers from different countries and different institutions. When suggesting reviewers, the Corresponding Author must provide an institutional email address for each suggested reviewer, or, if this is not possible to include other means of verifying the identity such as a link to a personal homepage, a link to the publication record or a researcher or author ID in the submission letter. Please note that the Journal may not use the suggestions, but suggestions are appreciated and may help facilitate the peer review process.

Authorship principles

These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to.

Authorship clarified

The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before the work is submitted.

The Publisher does not prescribe the kinds of contributions that warrant authorship. It is recommended that authors adhere to the guidelines for authorship that are applicable in their specific research field. In absence of specific guidelines it is recommended to adhere to the following guidelines*:

All authors whose names appear on the submission

1) made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work;

2) drafted the work or revised it critically for important intellectual content;

3) approved the version to be published; and

4) agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

* Based on/adapted from:

ICMJE, Defining the Role of Authors and Contributors,

Transparency in authors’ contributions and responsibilities to promote integrity in scientific publication, McNutt at all, PNAS February 27, 2018

Disclosures and declarations

All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate).

The decision whether such information should be included is not only dependent on the scope of the journal, but also the scope of the article. Work submitted for publication may have implications for public health or general welfare and in those cases it is the responsibility of all authors to include the appropriate disclosures and declarations.

Data transparency

All authors are requested to make sure that all data and materials as well as software application or custom code support their published claims and comply with field standards. Please note that journals may have individual policies on (sharing) research data in concordance with disciplinary norms and expectations.

Role of the Corresponding Author

One author is assigned as Corresponding Author and acts on behalf of all co-authors and ensures that questions related to the accuracy or integrity of any part of the work are appropriately addressed.

The Corresponding Author is responsible for the following requirements:

  • ensuring that all listed authors have approved the manuscript before submission, including the names and order of authors;
  • managing all communication between the Journal and all co-authors, before and after publication;*
  • providing transparency on re-use of material and mention any unpublished material (for example manuscripts in press) included in the manuscript in a cover letter to the Editor;
  • making sure disclosures, declarations and transparency on data statements from all authors are included in the manuscript as appropriate (see above).

* The requirement of managing all communication between the journal and all co-authors during submission and proofing may be delegated to a Contact or Submitting Author. In this case please make sure the Corresponding Author is clearly indicated in the manuscript.

Author contributions

In absence of specific instructions and in research fields where it is possible to describe discrete efforts, the Publisher recommends authors to include contribution statements in the work that specifies the contribution of every author in order to promote transparency. These contributions should be listed at the separate title page.

Examples of such statement(s) are shown below:

• Free text:

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by [full name], [full name] and [full name]. The first draft of the manuscript was written by [full name] and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Example: CRediT taxonomy:

• Conceptualization: [full name], …; Methodology: [full name], …; Formal analysis and investigation: [full name], …; Writing - original draft preparation: [full name, …]; Writing - review and editing: [full name], …; Funding acquisition: [full name], …; Resources: [full name], …; Supervision: [full name],….

For review articles where discrete statements are less applicable a statement should be included who had the idea for the article, who performed the literature search and data analysis, and who drafted and/or critically revised the work.

For articles that are based primarily on the student’s dissertation or thesis, it is recommended that the student is usually listed as principal author:

A Graduate Student’s Guide to Determining Authorship Credit and Authorship Order, APA Science Student Council 2006

Affiliation

The primary affiliation for each author should be the institution where the majority of their work was done. If an author has subsequently moved, the current address may additionally be stated. Addresses will not be updated or changed after publication of the article.

Changes to authorship

Authors are strongly advised to ensure the correct author group, the Corresponding Author, and the order of authors at submission. Changes of authorship by adding or deleting authors, and/or changes in Corresponding Author, and/or changes in the sequence of authors are not accepted after acceptance of a manuscript.

  • Please note that author names will be published exactly as they appear on the accepted submission!

Please make sure that the names of all authors are present and correctly spelled, and that addresses and affiliations are current.

Adding and/or deleting authors at revision stage are generally not permitted, but in some cases it may be warranted. Reasons for these changes in authorship should be explained. Approval of the change during revision is at the discretion of the Editor-in-Chief. Please note that journals may have individual policies on adding and/or deleting authors during revision stage.

Author identification

Authors are recommended to use their ORCID ID when submitting an article for consideration or acquire an ORCID ID via the submission process.

Deceased or incapacitated authors

For cases in which a co-author dies or is incapacitated during the writing, submission, or peer-review process, and the co-authors feel it is appropriate to include the author, co-authors should obtain approval from a (legal) representative which could be a direct relative.

Authorship issues or disputes

In the case of an authorship dispute during peer review or after acceptance and publication, the Journal will not be in a position to investigate or adjudicate. Authors will be asked to resolve the dispute themselves. If they are unable the Journal reserves the right to withdraw a manuscript from the editorial process or in case of a published paper raise the issue with the authors’ institution(s) and abide by its guidelines.

Confidentiality

Authors should treat all communication with the Journal as confidential which includes correspondence with direct representatives from the Journal such as Editors-in-Chief and/or Handling Editors and reviewers’ reports unless explicit consent has been received to share information.

Compliance with Ethical Standards

To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals.

Authors should include the following statements (if applicable) in a separate section entitled “Compliance with Ethical Standards” when submitting a paper:

  • Disclosure of potential conflicts of interest
  • Research involving Human Participants and/or Animals
  • Informed consent

Please note that standards could vary slightly per journal dependent on their peer review policies (i.e. single or double blind peer review) as well as per journal subject discipline. Before submitting your article check the instructions following this section carefully.

The corresponding author should be prepared to collect documentation of compliance with ethical standards and send if requested during peer review or after publication.

The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned guidelines. The author will be held responsible for false statements or failure to fulfill the above-mentioned guidelines.

Competing Interests

Authors are requested to disclose interests that are directly or indirectly related to the work submitted for publication. Interests within the last 3 years of beginning the work (conducting the research and preparing the work for submission) should be reported. Interests outside the 3-year time frame must be disclosed if they could reasonably be perceived as influencing the submitted work. Disclosure of interests provides a complete and transparent process and helps readers form their own judgments of potential bias. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate.

Editorial Board Members and Editors are required to declare any competing interests and may be excluded from the peer review process if a competing interest exists. In addition, they should exclude themselves from handling manuscripts in cases where there is a competing interest. This may include – but is not limited to – having previously published with one or more of the authors, and sharing the same institution as one or more of the authors. Where an Editor or Editorial Board Member is on the author list they must declare this in the competing interests section on the submitted manuscript. If they are an author or have any other competing interest regarding a specific manuscript, another Editor or member of the Editorial Board will be assigned to assume responsibility for overseeing peer review. These submissions are subject to the exact same review process as any other manuscript. Editorial Board Members are welcome to submit papers to the journal. These submissions are not given any priority over other manuscripts, and Editorial Board Member status has no bearing on editorial consideration.

Interests that should be considered and disclosed but are not limited to the following:

Funding: Research grants from funding agencies (please give the research funder and the grant number) and/or research support (including salaries, equipment, supplies, reimbursement for attending symposia, and other expenses) by organizations that may gain or lose financially through publication of this manuscript.

Employment: Recent (while engaged in the research project), present or anticipated employment by any organization that may gain or lose financially through publication of this manuscript. This includes multiple affiliations (if applicable).

Financial interests: Stocks or shares in companies (including holdings of spouse and/or children) that may gain or lose financially through publication of this manuscript; consultation fees or other forms of remuneration from organizations that may gain or lose financially; patents or patent applications whose value may be affected by publication of this manuscript.

It is difficult to specify a threshold at which a financial interest becomes significant, any such figure is necessarily arbitrary, so one possible practical guideline is the following: "Any undeclared financial interest that could embarrass the author were it to become publicly known after the work was published."

Non-financial interests: In addition, authors are requested to disclose interests that go beyond financial interests that could impart bias on the work submitted for publication such as professional interests, personal relationships or personal beliefs (amongst others). Examples include, but are not limited to: position on editorial board, advisory board or board of directors or other type of management relationships; writing and/or consulting for educational purposes; expert witness; mentoring relations; and so forth.

Primary research articles require a disclosure statement. Review articles present an expert synthesis of evidence and may be treated as an authoritative work on a subject. Review articles therefore require a disclosure statement.Other article types such as editorials, book reviews, comments (amongst others) may, dependent on their content, require a disclosure statement. If you are unclear whether your article type requires a disclosure statement, please contact the Editor-in-Chief.

Please note that, in addition to the above requirements, funding information (given that funding is a potential competing interest (as mentioned above)) needs to be disclosed upon submission of the manuscript in the peer review system. This information will automatically be added to the Record of CrossMark, however it is not added to the manuscript itself. Under ‘summary of requirements’ (see below) funding information should be included in the ‘Declarations’ section.

Summary of requirements

The above should be summarized in a statement and placed in a ‘Declarations’ section before the reference list under a heading of ‘Funding’ and/or ‘Competing interests’. Other declarations include Ethics approval, Consent, Data, Material and/or Code availability and Authors’ contribution statements.

Please see the various examples of wording below and revise/customize the sample statements according to your own needs.

When all authors have the same (or no) conflicts and/or funding it is sufficient to use one blanket statement.

Examples of statements to be used when funding has been received:

  • Partial financial support was received from [...]
  • The research leading to these results received funding from […] under Grant Agreement No[…].
  • This study was funded by […]
  • This work was supported by […] (Grant numbers […] and […]

Examples of statements to be used when there is no funding:

  • The authors did not receive support from any organization for the submitted work.
  • No funding was received to assist with the preparation of this manuscript.
  • No funding was received for conducting this study.
  • No funds, grants, or other support was received.

Examples of statements to be used when there are interests to declare:

  • Financial interests: Author A has received research support from Company A. Author B has received a speaker honorarium from Company Wand owns stock in Company X. Author C is consultant to company Y.

    Non-financial interests: Author C is an unpaid member of committee Z.

  • Financial interests: The authors declare they have no financial interests.

    Non-financial interests: Author A is on the board of directors of Y and receives no compensation as member of the board of directors.

  • Financial interests: Author A received a speaking fee from Y for Z. Author B receives a salary from association X. X where s/he is the Executive Director.

    Non-financial interests: none.

  • Financial interests: Author A and B declare they have no financial interests. Author C has received speaker and consultant honoraria from Company M and Company N. Dr. C has received speaker honorarium and research funding from Company M and Company O. Author D has received travel support from Company O.

    Non-financial interests: Author D has served on advisory boards for Company M, Company N and Company O.

Examples of statements to be used when authors have nothing to declare:

  • The authors have no relevant financial or non-financial interests to disclose.
  • The authors have no competing interests to declare that are relevant to the content of this article.
  • All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.
  • The authors have no financial or proprietary interests in any material discussed in this article.

Authors are responsible for correctness of the statements provided in the manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right to reject submissions that do not meet the guidelines described in this section.

Research involving human participants, their data or biological material

Ethics approval

When reporting a study that involved human participants, their data or biological material, authors should include a statement that confirms that the study was approved (or granted exemption) by the appropriate institutional and/or national research ethics committee (including the name of the ethics committee) and certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. If doubt exists whether the research was conducted in accordance with the 1964 Helsinki Declaration or comparable standards, the authors must explain the reasons for their approach, and demonstrate that an independent ethics committee or institutional review board explicitly approved the doubtful aspects of the study. If a study was granted exemption from requiring ethics approval, this should also be detailed in the manuscript (including the reasons for the exemption).

Retrospective ethics approval

If a study has not been granted ethics committee approval prior to commencing, retrospective ethics approval usually cannot be obtained and it may not be possible to consider the manuscript for peer review. The decision on whether to proceed to peer review in such cases is at the Editor's discretion.

Ethics approval for retrospective studies

Although retrospective studies are conducted on already available data or biological material (for which formal consent may not be needed or is difficult to obtain) ethics approval may be required dependent on the law and the national ethical guidelines of a country. Authors should check with their institution to make sure they are complying with the specific requirements of their country.

Ethics approval for case studies

Case reports require ethics approval. Most institutions will have specific policies on this subject. Authors should check with their institution to make sure they are complying with the specific requirements of their institution and seek ethics approval where needed. Authors should be aware to secure informed consent from the individual (or parent or guardian if the participant is a minor or incapable) See also section on Informed Consent.

Cell lines

If human cells are used, authors must declare in the manuscript: what cell lines were used by describing the source of the cell line, including when and from where it was obtained, whether the cell line has recently been authenticated and by what method. If cells were bought from a life science company the following need to be given in the manuscript: name of company (that provided the cells), cell type, number of cell line, and batch of cells.

It is recommended that authors check the NCBI database for misidentification and contamination of human cell lines. This step will alert authors to possible problems with the cell line and may save considerable time and effort.

Further information is available from the International Cell Line Authentication Committee (ICLAC).

Authors should include a statement that confirms that an institutional or independent ethics committee (including the name of the ethics committee) approved the study and that informed consent was obtained from the donor or next of kin.

Research Resource Identifiers (RRID)

Research Resource Identifiers (RRID) are persistent unique identifiers (effectively similar to a DOI) for research resources. This journal encourages authors to adopt RRIDs when reporting key biological resources (antibodies, cell lines, model organisms and tools) in their manuscripts.

Examples:

Organism: Filip1tm1a(KOMP)Wtsi RRID:MMRRC_055641-UCD

Cell Line: RST307 cell line RRID:CVCL_C321

Antibody: Luciferase antibody DSHB Cat# LUC-3, RRID:AB_2722109

Plasmid: mRuby3 plasmid RRID:Addgene_104005

Software: ImageJ Version 1.2.4 RRID:SCR_003070

RRIDs are provided by the Resource Identification Portal. Many commonly used research resources already have designated RRIDs. The portal also provides authors links so that they can quickly register a new resource and obtain an RRID.

Clinical Trial Registration

The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to assess, improve, maintain, promote or modify health, functioning or health conditions” and a health-related outcome is generally defined as a change in the health of a person or population as a result of an intervention.

To ensure the integrity of the reporting of patient-centered trials, authors must register prospective clinical trials (phase II to IV trials) in suitable publicly available repositories. For example www.clinicaltrials.gov or any of the primary registries that participate in the WHO International Clinical Trials Registry Platform.

The trial registration number (TRN) and date of registration should be included as the last line of the manuscript abstract.

For clinical trials that have not been registered prospectively, authors are encouraged to register retrospectively to ensure the complete publication of all results. The trial registration number (TRN), date of registration and the words 'retrospectively registered’ should be included as the last line of the manuscript abstract.

Standards of reporting

Springer Nature advocates complete and transparent reporting of biomedical and biological research and research with biological applications. Authors are recommended to adhere to the minimum reporting guidelines hosted by the EQUATOR Network when preparing their manuscript.

Exact requirements may vary depending on the journal; please refer to the journal’s Instructions for Authors.

Checklists are available for a number of study designs, including:

Randomised trials (CONSORT) and Study protocols (SPIRIT)

Observational studies (STROBE)

Systematic reviews and meta-analyses (PRISMA) and protocols (Prisma-P)

Diagnostic/prognostic studies (STARD) and (TRIPOD)

Case reports (CARE)

Clinical practice guidelines (AGREE) and (RIGHT)

Qualitative research (SRQR) and (COREQ)

Animal pre-clinical studies (ARRIVE)

Quality improvement studies (SQUIRE)

Economic evaluations (CHEERS)

Summary of requirements

The above should be summarized in a statement and placed in a ‘Declarations’ section before the reference list under a heading of ‘Ethics approval’.

Please see the various examples of wording below and revise/customize the sample statements according to your own needs.

Examples of statements to be used when ethics approval has been obtained:

• All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the Medical University of A (No. ...).

• This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University B (Date.../No. ...).

• Approval was obtained from the ethics committee of University C. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

• The questionnaire and methodology for this study was approved by the Human Research Ethics committee of the University of D (Ethics approval number: ...).

Examples of statements to be used for a retrospective study:

• Ethical approval was waived by the local Ethics Committee of University A in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.

• This research study was conducted retrospectively from data obtained for clinical purposes. We consulted extensively with the IRB of XYZ who determined that our study did not need ethical approval. An IRB official waiver of ethical approval was granted from the IRB of XYZ.

• This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of University B approved this study.

Examples of statements to be used when no ethical approval is required/exemption granted:

• This is an observational study. The XYZ Research Ethics Committee has confirmed that no ethical approval is required.

• The data reproduced from Article X utilized human tissue that was procured via our Biobank AB, which provides de-identified samples. This study was reviewed and deemed exempt by our XYZ Institutional Review Board. The BioBank protocols are in accordance with the ethical standards of our institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Authors are responsible for correctness of the statements provided in the manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right to reject submissions that do not meet the guidelines described in this section.

All individuals have individual rights that are not to be infringed. Individual participants in studies have, for example, the right to decide what happens to the (identifiable) personal data gathered, to what they have said during a study or an interview, as well as to any photograph that was taken. This is especially true concerning images of vulnerable people (e.g. minors, patients, refugees, etc) or the use of images in sensitive contexts. In many instances authors will need to secure written consent before including images.

Identifying details (names, dates of birth, identity numbers, biometrical characteristics (such as facial features, fingerprint, writing style, voice pattern, DNA or other distinguishing characteristic) and other information) of the participants that were studied should not be published in written descriptions, photographs, and genetic profiles unless the information is essential for scholarly purposes and the participant (or parent/guardian if the participant is a minor or incapable or legal representative) gave written informed consent for publication. Complete anonymity is difficult to achieve in some cases. Detailed descriptions of individual participants, whether of their whole bodies or of body sections, may lead to disclosure of their identity. Under certain circumstances consent is not required as long as information is anonymized and the submission does not include images that may identify the person.

Informed consent for publication should be obtained if there is any doubt. For example, masking the eye region in photographs of participants is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic profiles, authors should provide assurance that alterations do not distort meaning.

Exceptions where it is not necessary to obtain consent:

• Images such as x rays, laparoscopic images, ultrasound images, brain scans, pathology slides unless there is a concern about identifying information in which case, authors should ensure that consent is obtained.

• Reuse of images: If images are being reused from prior publications, the Publisher will assume that the prior publication obtained the relevant information regarding consent. Authors should provide the appropriate attribution for republished images.

Consent and already available data and/or biologic material

Regardless of whether material is collected from living or dead patients, they (family or guardian if the deceased has not made a pre-mortem decision) must have given prior written consent. The aspect of confidentiality as well as any wishes from the deceased should be respected.

Data protection, confidentiality and privacy

When biological material is donated for or data is generated as part of a research project authors should ensure, as part of the informed consent procedure, that the participants are made aware what kind of (personal) data will be processed, how it will be used and for what purpose. In case of data acquired via a biobank/biorepository, it is possible they apply a broad consent which allows research participants to consent to a broad range of uses of their data and samples which is regarded by research ethics committees as specific enough to be considered “informed”. However, authors should always check the specific biobank/biorepository policies or any other type of data provider policies (in case of non-bio research) to be sure that this is the case.

Consent to Participate

For all research involving human subjects, freely-given, informed consent to participate in the study must be obtained from participants (or their parent or legal guardian in the case of children under 16) and a statement to this effect should appear in the manuscript. In the case of articles describing human transplantation studies, authors must include a statement declaring that no organs/tissues were obtained from prisoners and must also name the institution(s)/clinic(s)/department(s) via which organs/tissues were obtained. For manuscripts reporting studies involving vulnerable groups where there is the potential for coercion or where consent may not have been fully informed, extra care will be taken by the editor and may be referred to the Springer Nature Research Integrity Group.

Consent to Publish

Individuals may consent to participate in a study, but object to having their data published in a journal article. Authors should make sure to also seek consent from individuals to publish their data prior to submitting their paper to a journal. This is in particular applicable to case studies. A consent to publish form can be found

here. (Download docx, 36 kB)

Summary of requirements

The above should be summarized in a statement and placed in a ‘Declarations’ section before the reference list under a heading of ‘Consent to participate’ and/or ‘Consent to publish’. Other declarations include Funding, Competing interests, Ethics approval, Consent, Data and/or Code availability and Authors’ contribution statements.

Please see the various examples of wording below and revise/customize the sample statements according to your own needs.

Sample statements for "Consent to participate":

Informed consent was obtained from all individual participants included in the study.

Informed consent was obtained from legal guardians.

Written informed consent was obtained from the parents.

Verbal informed consent was obtained prior to the interview.

Sample statements for “Consent to publish”:

The authors affirm that human research participants provided informed consent for publication of the images in Figure(s) 1a, 1b and 1c.

The participant has consented to the submission of the case report to the journal.

Patients signed informed consent regarding publishing their data and photographs.

Sample statements if identifying information about participants is available in the article:

Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

Authors are responsible for correctness of the statements provided in the manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right to reject submissions that do not meet the guidelines described in this section.

Images will be removed from publication if authors have not obtained informed consent or the paper may be removed and replaced with a notice explaining the reason for removal.

We ask that all authors include statements in their manuscripts declaring whether there are any conflicts of interest with their article. Papers will not be published until these statements have been provided. For more detailed information regarding ethical requirements for our authors please read the Instructions to Authors link on this page.

After acceptance

Upon acceptance, your article will be exported to Production to undergo typesetting. Shortly after this you will receive two e-mails. One contains a request to confirm your affiliation, choose the publishing model for your article, as well as to arrange rights and payment of any associated publication cost. A second e-mail containing a link to your article’s proofs will be sent once typesetting is completed.

Article publishing agreement

Depending on the ownership of the journal and its policies, you will either grant the Publisher an exclusive licence to publish the article or will be asked to transfer copyright of the article to the Publisher.

Offprints

Offprints can be ordered by the corresponding author.

Color illustrations

Online publication of color illustrations is free of charge. For color in the print version, authors will be expected to make a contribution towards the extra costs.

Proof reading

The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.

After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.

Online First

The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.

Open Choice

Open Choice allows you to publish open access in more than 1850 Springer Nature journals, making your research more visible and accessible immediately on publication.

Article processing charges (APCs) vary by journal – view the full list

Benefits:

  • Increased researcher engagement: Open Choice enables access by anyone with an internet connection, immediately on publication.
  • Higher visibility and impact: In Springer hybrid journals, OA articles are accessed 4 times more often on average, and cited 1.7 more times on average*.

  • Easy compliance with funder and institutional mandates: Many funders require open access publishing, and some take compliance into account when assessing future grant applications.

It is easy to find funding to support open access – please see our funding and support pages for more information.

*) Within the first three years of publication. Springer Nature hybrid journal OA impact analysis, 2018.

Open Choice

Funding and Support pages

Copyright and license term – CC BY

Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.

Find more about the license agreement

Open access publishing

To find out more about publishing your work Open Access in Clinical and Translational Imaging, including information on fees, funding and licenses, visit our Open access publishing page.

Navigation